Psyence Biomedical Ltd.PBM

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · Canada · psyencebiomed.com

Psyence Biomedical is a multi-asset, vertically integrated biopharmaceutical company developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic therapeutics for mental health disorders. It holds an ownership interest in PsyLabs, a GMP-compliant psychedelic active-pharmaceutical-ingredient manufacturer. The company brands itself Psyence BioMed; the Nasdaq symbol PBM is unrelated to the TSXV row PBM.V (Pacific Bay Minerals).

Key ratios

ROA

-31.3%2026

2025 -54.2%2024 -126.4%

ROE

-58.6%2026

Recent news

Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development 2026-09-14 · GlobeNewswire Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development 2026-08-18 · GlobeNewswire

Track PBM in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer